The 2026 RCT That Just Changed Everything for Minoxidil Beards

Since 2016, the minoxidil-for-beards community has been leaning on a single randomized controlled trial — Ingprasert et al., 48 men, 3% solution, 16 weeks. It was good science, but it was a small study, nearly a decade old, and critics had a fair point: one RCT doesn't prove much.

That argument is now significantly weaker.

In March 2026, Wattanawinitchai and colleagues at Mahidol University in Bangkok published what is now the largest prospective, randomized, double-blind, placebo-controlled trial specifically measuring minoxidil's effect on facial hair growth. The numbers are unambiguous. Every primary endpoint favored minoxidil. The safety profile was clean. And quality of life improved dramatically in the treatment group.

If you're on the fence about starting minoxidil for your beard — or you've been looking for clinical evidence to show a skeptical dermatologist — this is the study you've been waiting for.

The Study: Wattanawinitchai et al. 2026

Here's the study design:

• 69 participants — all on stable hormone therapy with incomplete facial hair development
• Randomized to either topical 3% minoxidil solution or placebo
• Double-blind — neither participants nor investigators knew who got the real thing
• Measured: beard density (hairs/cm²), hair diameter (μm), mustache density, mustache diameter, physician-assessed and patient-assessed facial hair scores (mFGS), quality of life (DLQI), and patient satisfaction

The design is rigorous. This isn't a case report or an observational study. It's the gold standard of evidence — randomized, blinded, placebo-controlled — with a larger sample size than the Ingprasert RCT that the entire community has relied on for the past decade.

The Results: Every Endpoint Hit

The minoxidil group (n=34) outperformed placebo (n=35) on every measured outcome. Not some of them. Not most of them. All of them.

Beard Density

The minoxidil group gained an average of 11.16 hairs per cm² in the beard area, compared to essentially zero (0.08 hairs/cm²) in the placebo group. The difference was statistically significant (p = 0.01). This isn't marginal improvement — it's a 139x difference between the treatment and control groups.

Beard Diameter

Hair diameter increased by 5.37 μm in the minoxidil group vs a slight decrease (-0.33 μm) in placebo (p = 0.01). This is the first large RCT to measure and confirm that topical minoxidil increases the thickness of facial hair — not just the count. Thicker hairs mean more visible beard density, even with the same number of follicles.

Mustache Results

The mustache area showed even more dramatic improvement: 18.45 hairs/cm² gained vs 1.74 in placebo (p = 0.003). Mustache diameter also increased significantly (4.83 vs 1.31 μm, p = 0.008). This is notable because the mustache area is typically one of the slower-responding zones in community-reported results.

Clinical Scoring

Both physician-assessed and patient-assessed modified Ferriman-Gallwey scores showed significant improvements in the minoxidil group (p < 0.05 for both). When doctors could see the difference and patients could feel the difference, the improvement wasn't just measurable — it was meaningful.

Quality of Life

The Dermatology Life Quality Index (DLQI) dropped from a median of 5 to 1.5 in the minoxidil group, compared to 4 to 3 in placebo (p < 0.05). In clinical terms, this means the treatment group went from "moderate effect on daily life" to "no effect" — their facial hair concerns were essentially resolved.

Safety

Adverse events were minimal and comparable between the two groups. No serious adverse events. No cardiac events. No dropouts due to side effects. This aligns with the safety profile seen in the Ingprasert RCT and the Almutairi 2025 meta-analysis.

The Numbers That Matter: How This Stacks Against Existing Evidence

The Wattanawinitchai trial is the largest prospective RCT on the list. It measures more endpoints than any prior study (density + diameter + clinical scoring + QoL + satisfaction). And it confirms the findings of every study before it while adding new data on hair diameter and quality of life — two outcomes that previous studies didn't measure or didn't report.

How This Changes the Evidence Landscape

Before this study, the evidence hierarchy for minoxidil on facial hair looked like this: one RCT (Ingprasert), one twin case report (Shokravi), one small clinical study (Marinelli), and one meta-analysis (Almutairi) that largely drew from the same pool of studies.

The common criticism was fair: the evidence was thin. One RCT with 48 subjects isn't robust. Case reports are anecdotal by nature. And the meta-analysis could only be as strong as the underlying studies it reviewed.

Wattanawinitchai 2026 substantially strengthens the foundation. Here's what's different:

• Larger sample size — 69 subjects vs 48 in Ingprasert. More statistical power, more reliable results.
• Multiple objective endpoints — density AND diameter measured independently for beard AND mustache areas. Previous studies typically reported only one or two metrics.
• Patient-reported outcomes included — quality of life and satisfaction scores capture what objective measurements miss: whether people actually feel better about their faces.
• Clean safety data — no cardiac events, no serious adverse effects, comparable adverse event rates between treatment and placebo groups.

What This Means for Your Beard Journey

If You're Considering Starting

The clinical evidence supporting topical 3% minoxidil for facial hair is now stronger than it's ever been. Two independent RCTs and a systematic review of 19 studies all point in the same direction. If you've been waiting for "enough proof" — this is it. The standard protocol from the clinical trials: 3% minoxidil solution applied twice daily to the beard area, with results measured at 16 weeks.

If You're Already Using It

You now have better data to understand what's happening. The diameter improvements in this study confirm something the community has observed anecdotally for years: minoxidil doesn't just add more hairs — it makes existing hairs thicker. If you're seeing thicker, darker hairs in the mirror, the clinical data now validates that experience.

If You're Talking to a Doctor

Print this study. Seriously. One of the biggest barriers to getting medical support for minoxidil beard growth has been the "there's only one study" objection. That objection is now outdated. The Wattanawinitchai trial, combined with the Almutairi meta-analysis, provides the kind of evidence that most dermatologists consider sufficient for clinical recommendation.

The 3% vs 5% Question

Both RCTs used 3% concentration. The community predominantly uses 5% (Rogaine/Kirkland) because that's what's available over the counter. Extrapolating from scalp studies, 5% is likely at least as effective — but the rigorous clinical evidence is specifically on 3%. If you want to follow the studied protocol exactly, 3% twice daily is the tested dose. If you prefer the practical route, 5% foam once or twice daily is what the majority of successful users report.

Frequently Asked Questions